

RNS Number : 3991R
EKF Diagnostics Holdings PLC
01 March 2023

EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")

Notice of Preliminary Results and Investor Presentation

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, will announce its preliminary results for the year ended 31 December 2022, on Tuesday 28 March 2023.

Investor Presentation

Julian Baines, Executive Chair, and Marc Davies, Chief Financial Officer, will be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 4.30 pm on Tuesday 28 March 2023. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:
<https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor>

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Julian Baines, Executive Chair / Marc Davies, CFO **Tel: +44 (0)29 2071 0570**

Singer Capital Markets (Nominated Adviser & Joint Broker) **Tel: +44 (0)20 7496 3000**
Aubrey Powell / George Tzimas / Oliver Platts

Walbrook PR Limited **Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com**
Paul McManus / Lianne Applegarth **Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303**

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

Point-of-Care	Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
Central Laboratory	Clinical chemistry, Small lab analysers, Centrifuges <i>Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin</i>
Life Sciences	Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing	Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
Laboratory Testing	Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORSELFWAEDSEFE Anonymous (not verified) Notice of Results and Investor Presentation
33336014 A Wed, 03/01/2023 - 07:00 LSE RNS Advance Notice of Results EKF